RxSight, Inc. (NASDAQ:RXST) Director Tamara Fountain Sells 7,000 Shares

RxSight, Inc. (NASDAQ:RXST - Get Free Report) Director Tamara Fountain sold 7,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

RxSight Stock Performance

Shares of NASDAQ:RXST traded up $0.66 during trading hours on Monday, hitting $26.50. 408,572 shares of the company's stock traded hands, compared to its average volume of 526,953. The company's fifty day simple moving average is $30.56 and its two-hundred day simple moving average is $41.00. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -31.93 and a beta of 1.22. RxSight, Inc. has a 52 week low of $24.64 and a 52 week high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The business had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. On average, analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On RxSight

Several hedge funds have recently modified their holdings of RXST. Quarry LP raised its holdings in RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company's stock worth $32,000 after buying an additional 288 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of RxSight during the third quarter valued at approximately $34,000. Private Trust Co. NA purchased a new stake in shares of RxSight in the 4th quarter valued at approximately $34,000. State of Wyoming acquired a new position in RxSight in the 4th quarter worth approximately $37,000. Finally, Coppell Advisory Solutions LLC boosted its stake in RxSight by 108.9% in the 4th quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock worth $44,000 after purchasing an additional 672 shares during the period. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on RXST shares. UBS Group started coverage on shares of RxSight in a report on Friday, December 6th. They issued a "buy" rating and a $52.00 price objective on the stock. Wells Fargo & Company reduced their price objective on RxSight from $40.00 to $35.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $43.00 target price on shares of RxSight in a research report on Wednesday, February 26th. Stifel Nicolaus reduced their price target on RxSight from $35.00 to $33.00 and set a "hold" rating for the company in a research report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. decreased their target price on shares of RxSight from $62.00 to $40.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, RxSight currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.